Stock Analysis on Net

Elevance Health Inc. (NYSE:ELV)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Elevance Health Inc., profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The profitability metrics exhibited varied trends over the observed period. Generally, a decline in profitability ratios is apparent from 2022 through 2025, although the rate of decline differs across metrics. Initial values demonstrate a relatively stable performance in the first half of the period, followed by a more pronounced downward trajectory in the latter half.

Gross Profit Margin
The gross profit margin began at 16.89% and generally fluctuated within a narrow range until mid-2024. A noticeable decrease commenced in the latter half of 2024, continuing into 2025, ultimately reaching 14.26%. This indicates increasing costs relative to revenue.
Operating Profit Margin
The operating profit margin followed a similar pattern to the gross profit margin, starting at 5.10% and declining to 3.33% by the end of the period. The rate of decline accelerated in 2024 and 2025, suggesting increasing operating expenses or decreasing operational efficiency. The margin experienced a more consistent decline than the gross profit margin, indicating that cost control measures were less effective at the operating level.
Net Profit Margin
The net profit margin demonstrated a consistent, albeit gradual, decline from 4.37% in March 2022 to 2.87% in December 2025. This suggests that factors beyond cost of goods sold and operating expenses, such as interest or taxes, also contributed to the overall decrease in profitability. The decline mirrors the trends observed in the gross and operating profit margins, but is slightly more pronounced.
Return on Equity (ROE)
Return on equity began at 17.36% and decreased to 12.90% over the period. The decline was relatively steady until 2024, after which the rate of decrease accelerated. This indicates a diminishing ability to generate profit from shareholder investments.
Return on Assets (ROA)
Return on assets exhibited a similar downward trend, starting at 6.21% and ending at 4.66%. The rate of decline was consistent throughout the period, suggesting a decreasing efficiency in utilizing assets to generate earnings. The ROA decline closely parallels the ROE decline, indicating that the decrease in profitability is impacting returns to both shareholders and overall asset utilization.

In summary, the observed trends indicate a consistent erosion of profitability across all measured ratios. The acceleration of these declines in the later quarters suggests potential underlying issues requiring further investigation. The consistent decline across multiple ratios points to systemic challenges rather than isolated incidents.


Return on Sales


Return on Investment


Gross Profit Margin

Elevance Health Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Gross profit
Operating revenue
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Gross profit margin = 100 × (Gross profitQ4 2025 + Gross profitQ3 2025 + Gross profitQ2 2025 + Gross profitQ1 2025) ÷ (Operating revenueQ4 2025 + Operating revenueQ3 2025 + Operating revenueQ2 2025 + Operating revenueQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibited relative stability between March 31, 2022, and December 31, 2023, fluctuating within a narrow range. However, a discernible downward trend emerged in the subsequent periods, continuing through December 31, 2025. While gross profit generally increased in absolute terms over the observed period, the rate of increase in operating revenue outpaced that of gross profit, contributing to the margin compression.

Initial Period (Mar 31, 2022 – Dec 31, 2023)
The gross profit margin remained consistently around 16.8%, with minor quarterly variations. It began at 16.89% in March 2022, dipped to 16.79% in June 2022 and December 2023, and peaked at 16.90% in March 2023. These fluctuations suggest a stable cost structure relative to revenue during this timeframe.
Downward Trend (Mar 31, 2024 – Dec 31, 2025)
Beginning in March 2024, the gross profit margin began a consistent decline. It increased to 17.16% in June 2024, but then decreased to 16.62% in September 2024, 15.92% in December 2024, 15.66% in March 2025, 14.93% in June 2025, 14.45% in September 2025, and finally reached 14.26% by December 2025. This represents a significant reduction from the levels observed in the earlier periods.
Gross Profit and Revenue Relationship
While gross profit increased from US$6,788 million in March 2022 to US$8,470 million in March 2025, operating revenue experienced a more substantial increase, rising from US$37,886 million to US$48,765 million over the same period. This disparity in growth rates is a primary driver of the observed margin compression. The increase in revenue did not translate proportionally into increased gross profit.

The decline in gross profit margin warrants further investigation to determine the underlying causes. Potential factors could include increased cost of goods sold, changes in product mix, pricing pressures, or a combination of these elements. Continued monitoring of this trend is recommended.


Operating Profit Margin

Elevance Health Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Operating income
Operating revenue
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Operating profit margin = 100 × (Operating incomeQ4 2025 + Operating incomeQ3 2025 + Operating incomeQ2 2025 + Operating incomeQ1 2025) ÷ (Operating revenueQ4 2025 + Operating revenueQ3 2025 + Operating revenueQ2 2025 + Operating revenueQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operating profit margin exhibited a generally declining trend over the observed period, punctuated by periods of relative stability and modest increases. Initial values hovered around the 5.1% mark in the first quarter of 2022, before gradually decreasing through the end of 2023. A slight recovery occurred in the first half of 2024, followed by a more pronounced decline in the latter half of the year and into the first half of 2025.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The operating profit margin began at 5.10% and experienced a modest decrease to 4.94% over this period. This represents a relatively stable performance with a slight contraction in profitability. Operating income decreased from $2,318 million to $1,121 million, while operating revenue remained relatively consistent.
Recovery and Subsequent Decline (Mar 31, 2023 – Dec 31, 2024)
A recovery was observed in the first half of 2023, with the margin reaching 4.99% and 4.96% respectively. However, this was followed by a decline to 4.16% by the end of 2024. This period demonstrates increased volatility, with operating income fluctuating significantly while operating revenue showed a moderate increase. The most substantial decrease in operating profit margin occurred between September 30, 2024 and December 31, 2024.
Recent Performance (Mar 31, 2025 – Dec 31, 2025)
The operating profit margin continued its downward trajectory, reaching 3.33% by December 31, 2025. This represents the lowest point in the observed period. Operating income experienced a dramatic reduction, falling from $3,015 million to $145 million, while operating revenue experienced a slight decrease. This suggests a significant impact on profitability during this period.

Overall, the operating profit margin demonstrates a clear trend of decreasing profitability. While there were periods of stabilization and minor improvement, the overall direction is downward, with the most significant decline occurring in the most recent quarters. Further investigation into the factors driving the decrease in operating income relative to operating revenue is warranted.


Net Profit Margin

Elevance Health Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Shareholders’ net income
Operating revenue
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Net profit margin = 100 × (Shareholders’ net incomeQ4 2025 + Shareholders’ net incomeQ3 2025 + Shareholders’ net incomeQ2 2025 + Shareholders’ net incomeQ1 2025) ÷ (Operating revenueQ4 2025 + Operating revenueQ3 2025 + Operating revenueQ2 2025 + Operating revenueQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The net profit margin exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a relatively stable margin, followed by a period of decline, and then a degree of recovery, though not to the initial levels.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The net profit margin began at 4.37% in March 2022 and experienced a gradual decrease through the end of 2022, concluding at 3.87%. This represents a decline of 0.50 percentage points over the four quarters. While still representing a healthy margin, this initial trend suggests potential pressures on profitability.
Stabilization and Slight Increase (Mar 31, 2023 – Jun 30, 2023)
The first half of 2023 showed a period of stabilization, with the net profit margin holding steady at 3.89% for two consecutive quarters. This suggests that the factors impacting profitability in late 2022 were potentially mitigated or stabilized.
Subsequent Decline (Sep 30, 2023 – Dec 31, 2024)
From September 2023 through December 2024, a more pronounced downward trend emerged. The net profit margin decreased from 3.63% to 3.41%, continuing to a low of 2.87% by the end of 2025. This represents a significant reduction in profitability over this period, totaling 0.76 percentage points.
Recent Performance (Mar 31, 2024 – Dec 31, 2025)
The net profit margin demonstrated considerable volatility in the latter part of the period. A peak of 3.93% was observed in June 2024, followed by a sharp decline to 3.41% in the subsequent quarter. The final quarter of 2025 registered a net profit margin of 2.87%, indicating a sustained period of reduced profitability compared to earlier periods.
Overall Trend
Overall, the net profit margin experienced a general decline from the beginning of the observed period to the end. While periods of stabilization occurred, the overarching trend indicates increasing pressure on profitability. The most substantial decrease occurred in the latter half of the period, warranting further investigation into the underlying factors contributing to this decline.

Return on Equity (ROE)

Elevance Health Inc., ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Shareholders’ net income
Shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
Abbott Laboratories
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
ROE = 100 × (Shareholders’ net incomeQ4 2025 + Shareholders’ net incomeQ3 2025 + Shareholders’ net incomeQ2 2025 + Shareholders’ net incomeQ1 2025) ÷ Shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Equity (ROE) for the analyzed period demonstrates a generally declining trend, although with some quarterly fluctuations. Initial values are relatively stable before a noticeable decrease in the latter part of the observed timeframe. Shareholders’ net income exhibits volatility, while Shareholders’ equity consistently increases, influencing the observed ROE pattern.

Overall Trend
ROE begins at 17.36% in March 2022 and generally decreases to 12.90% by December 2025. While there are quarterly variations, the overall direction is downward. The most significant declines occur between September 2023 and December 2023, and again between December 2024 and December 2025.
Initial Stability (March 2022 - June 2022)
From March 2022 to June 2022, ROE remains relatively consistent, fluctuating between 17.04% and 17.36%. This period suggests a stable relationship between net income and shareholders’ equity.
Mid-Period Fluctuations (September 2022 - June 2023)
Between September 2022 and June 2023, ROE experiences moderate fluctuations, ranging from 15.82% to 17.26%. This suggests some variability in profitability relative to equity during this period. Net income decreases in this period, but is offset by increasing equity.
Downward Trend Acceleration (September 2023 - December 2025)
From September 2023 onwards, the decline in ROE accelerates. ROE decreases from 15.82% to 12.90% over this period. This coincides with a period where net income experiences more substantial declines, and while equity continues to grow, it does not fully compensate for the reduced profitability. The largest single-quarter decrease occurs between December 2024 and December 2025.
Shareholders’ Equity Impact
Shareholders’ equity consistently increases throughout the analyzed period, rising from US$35,975 million to US$43,882 million. This growth in equity partially mitigates the impact of fluctuating net income on ROE, but the increasing equity base requires higher net income to maintain the same ROE level.
Net Income Impact
Shareholders’ net income demonstrates significant quarterly variability. While there are periods of growth, the overall trend from the beginning to the end of the period is a decrease in net income. This decline in net income is a primary driver of the observed ROE decline, particularly in the latter half of the period.

Return on Assets (ROA)

Elevance Health Inc., ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Shareholders’ net income
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
Abbott Laboratories
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
ROA = 100 × (Shareholders’ net incomeQ4 2025 + Shareholders’ net incomeQ3 2025 + Shareholders’ net incomeQ2 2025 + Shareholders’ net incomeQ1 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibited a generally declining trend over the observed period, although with some quarterly fluctuations. Initial values were relatively stable, followed by a period of more pronounced variability and a subsequent leveling off towards the end of the analyzed timeframe.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The ROA began at 6.21% and experienced a gradual decrease to 5.86% by the end of 2022. This represents a modest decline over four consecutive quarters, suggesting a slight reduction in profitability relative to the asset base during this period. The fluctuations within this timeframe were minimal.
Transition and Volatility (Mar 31, 2023 – Dec 31, 2023)
The ROA demonstrated increased volatility between March 2023 and December 2023. It initially rose to 5.87% in June 2023, before declining significantly to 5.50% in September 2023, and then further to 5.50% in December 2023. This period indicates a more dynamic relationship between net income and total assets.
Continued Decline and Stabilization (Mar 31, 2024 – Dec 31, 2025)
A continued downward trend was observed through the first half of 2024, reaching 5.51% in September 2024 and 5.12% in December 2024. The ROA then stabilized somewhat, fluctuating between 4.40% and 4.94% in 2025, concluding at 4.66% in December 2025. This suggests that while profitability relative to assets continued to decrease, the rate of decline slowed in the latter part of the period.
Overall Trend
From the initial value of 6.21% in March 2022, the ROA decreased to 4.66% by December 2025. This represents an overall decrease of approximately 25% in the ROA over the analyzed timeframe. The most significant declines occurred between June 2023 and December 2024.

The observed trends suggest a potential weakening in the efficiency with which assets are being utilized to generate profit. Further investigation into the underlying drivers of both net income and asset composition would be necessary to fully understand these changes.